Matt Larew is ranked #721 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Matt Larew

Q: How accurate are Matt Larew's stock ratings?

About 78% of Matt's ratings were profitable over a one-year hold, with an average return of +17.9% per rating, measured by 13Foresight from historical prices.

William Blair

Wall Street Analyst

★★★★☆

#721

on 13Foresight · ranked by our own returns

78%

Success Rate

+17.9%

Average Return

56 of 72 calls profitable · +35.0% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 78% of Matt Larew's ratings turned a profit when each position was held for 1 year — averaging +17.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

88 Buy 38 Hold 3 Sell

Matt's Stock Coverage 36 ratings · 2026-09-28

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
AVTR Avantor	Sep 21, 2026	HOLD	Buy +4.2% avg upside 26 analysts	—	+0.9%	·
VCYT Veracyte	Sep 15, 2026	BUY	Strong Buy +15.2% avg upside 19 analysts	—	+13.2%	·
GH Guardant Health	Sep 08, 2026	BUY	Strong Buy -5.2% avg upside 32 analysts	—	+10.7%	·
NEO NeoGenomics	Aug 27, 2026	HOLD	Buy -7.7% avg upside 18 analysts	—	+3.7%	·
QGEN Qiagen	Aug 24, 2026	HOLD	Buy -2.7% avg upside 24 analysts	—	+5.7%	·
SERA Sera Prognostics	Aug 20, 2026	BUY	Strong Buy +265.2% avg upside 8 analysts	—	-2.9%	·
MDXH MDxHealth	Aug 14, 2026	HOLD	Strong Buy +960.3% avg upside 9 analysts	—	-27.0%	·
TECH Bio-Techne	Aug 12, 2026	HOLD	Buy +14.9% avg upside 21 analysts	—	+0.5%	·
MASS 908 Devices	Aug 11, 2026	BUY	Strong Buy +9.3% avg upside 5 analysts	—	+14.3%	·
MRVI Maravai Lifesciences Holdings	Aug 07, 2026	HOLD	Strong Buy +100.4% avg upside 17 analysts	—	+15.1%	·
TXG 10x Genomics	Aug 07, 2026	BUY	Buy -45.1% avg upside 18 analysts	—	+64.7%	·
NTRA Natera	Aug 07, 2026	BUY	Strong Buy -22.0% avg upside 28 analysts	—	+28.1%	·
TKNO Alpha Teknova	Aug 06, 2026	BUY	Strong Buy +28.6% avg upside 8 analysts	—	+42.9%	·
BLLN BillionToOne, Inc. Class A	Aug 06, 2026	BUY	Strong Buy -0.4% avg upside 10 analysts	—	+13.3%	·
BDSX Biodesix	Aug 06, 2026	BUY	Strong Buy +24.8% avg upside 9 analysts	—	+31.7%	·
STVN Stevanato Group	Aug 05, 2026	BUY	Strong Buy +29.6% avg upside 13 analysts	—	+7.0%	·
WAT Waters	Aug 04, 2026	BUY	Strong Buy -7.8% avg upside 31 analysts	—	+9.5%	·
TWST Twist Bioscience	Aug 03, 2026	BUY	Strong Buy -50.1% avg upside 15 analysts	—	+80.9%	·
CDNA CareDx	Aug 03, 2026	HOLD	Buy -30.7% avg upside 18 analysts	—	+33.1%	·
ATR AptarGroup	Jul 31, 2026	HOLD	Strong Buy +14.3% avg upside 14 analysts	—	-7.9%	·
TEM Tempus AI, Inc. Class A	Jul 31, 2026	HOLD	Strong Buy -18.7% avg upside 24 analysts	—	+92.1%	·
ADPT Adaptive Biotechnologies	Jul 30, 2026	BUY	Strong Buy -15.1% avg upside 15 analysts	—	+21.7%	·
OPCH Option Care Health	Jul 29, 2026	BUY	Strong Buy +27.4% avg upside 20 analysts	—	-4.1%	·
RGEN Repligen	Jul 28, 2026	BUY	Strong Buy -9.4% avg upside 25 analysts	—	+30.5%	·
TMO Thermo Fisher	Jul 24, 2026	BUY	Strong Buy -8.8% avg upside 40 analysts	—	+18.7%	·
WST West Pharmaceutical Services	Jul 23, 2026	BUY	Strong Buy -0.7% avg upside 18 analysts	—	+4.9%	·
DHR Danaher	Jul 22, 2026	BUY	Strong Buy -5.5% avg upside 47 analysts	—	+24.9%	·
MXCT MaxCyte	Jul 02, 2026	HOLD	Strong Buy +247.9% avg upside 5 analysts	—	-2.1%	·
DNA Ginkgo Bioworks Holdings	May 11, 2026	SELL	Strong Sell -33.1% avg upside 6 analysts	—	-22.9%	·
CRL Charles River Labs	Oct 11, 2025	BUY	Strong Buy -15.5% avg upside 35 analysts	—	+71.6%	·
USPH US Physical Therapy	Oct 08, 2024	HOLD	Strong Buy +9.2% avg upside 12 analysts	—	+19.2%	·
NL:LIGHT Signify NV	Aug 22, 2022	BUY	Hold +85.9% avg upside 13 analysts	—	-9.8%	·
INNV InnovAge Holding	Sep 22, 2021	HOLD	Hold -6.9% avg upside 12 analysts	—	-27.3%	·
DVA DaVita	Sep 11, 2019	HOLD	Buy -3.8% avg upside 17 analysts	—	+47.2%	·
LH Labcorp Holdings	Dec 03, 2018	BUY	Strong Buy -13.2% avg upside 37 analysts	—	+15.0%	·
EHC Encompass Health	Nov 21, 2017	BUY	Strong Buy -5.3% avg upside 22 analysts	—	+48.5%	·

🔒 31 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Matt Larew — Frequently Asked Questions

How accurate are Matt Larew's stock ratings?

Based on the calls 13Foresight could measure, about 78% of Matt's ratings were profitable over a one-year hold, with an average return of +17.9% per rating, or +35.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Matt ranked on 13Foresight?

Matt Larew is currently ranked #721 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Matt cover?

Matt most recently has ratings on AVTR, VCYT, GH, NEO, QGEN, SERA, MDXH, TECH, MASS, MRVI, TXG, NTRA and 24 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Matt Larew

Rating Distribution

Welcome to 13Foresight!